circle

A PIPELINE POWERED BYPASSION

PUBLICATIONS AND PRESENTATIONS

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Journal of Medicinal Chemistry
Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER, Cremin P, Zamora J, Hartman J, Schaletzy J, Wehri E, Robertson LA, Malik FI, Morgan BP
October 4, 2021

REDWOOD-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, Aficamten, In Obstructive Hypertrophic Cardiomyopathy

Presentation, Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Maron, M, et al
Denver, CO
September 12, 2021

Effect of Omecamtiv Mecarbil in Black Patients with Heart Failure and Reduced Ejection Fraction

Presentation, Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Lanfear, DE, et al
Denver, CO
September 12, 2021

Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based Claims Analysis)

The American Journal of Cardiology
Butzner M, Maron M, Sarocco P, et al
September 6, 2021

Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event

Journal of the American Heart Association
Carnicelli AP, Clare R, Hofmann P, Chiswell K, DeVore AD, Vemulapalli S, Felker GM, Sarocco P, Mentz RJ
September 2, 2021